Objective To investigate the effect of pegylated interferon combined thymopeptideenteric-coated tablets on CXCR3, CCR6 and serum IL-2 and soluble ligand in patients with chronic hepatitis.Methods 125 patients with chronic hepatitis B patients from June 2015 to June 2016 in our hospital were selected and divided into observation group 62 cases and control group 63 cases.The observation group was treated with pegylated interferon combined thymopeptideenteric-coated tablets, and the control group was treated with thymopeptideenteric-coated tablets, the expression of T cells in patients with CXCR3 and CCR6 was detected by flow cytometry, the serum levels of interleukin-2 and soluble interleukin-2 receptorwere measured by enzyme-linked immunosorbent assay, and compared the treatment of two groups of patients.Results After treatment, the levels of IL-2 and sIL-2R in the observation groupwere (16.4 ±5.6), (9.4 ±2.1), significantly lower than that in the control group, while CXCR3 and CCR6 were (5.8 ±0.9), (5.54 ±1.2), significantly higher than the control group, the difference was statistically significant (P<0.05), the levels of HBsAg, HBeAg and HBV-DNA in the observation group were (1.5 ±0.4), (1.6 ±0.9), (1.6 ±0.3), significantly lower than those in the control group, the difference was statistically significant (P<0.05), the levels of ALT, AST, TBIL, IBIL in the observation groupwere (34.5 ±8.7), (31.4 ±6.9), (14.6 ± 6.9), (9.4 ±2.9), significantly lower than those in the control group, the difference was statistically significant (P<0.05).Conclusion Interferon combined thymopeptideenteric-coated tablets therapy for chronic hepatitis B is helpful to improve the level of chemokine receptor and inhibit the degree of inflammatory reaction.It can help to improve liver function and inhibit viral replication in patients with hepatitis B.It is better than the treatment of chronic hepatitis with thymosin alone.%目的 分析聚乙二醇干扰素联合胸腺肽肠溶片对慢性肝炎患者外周血CXCR3、CCR6、白细胞介素-2(IL-2)及其可溶性配体水平的影响.方法 选取2015年6月~2016年6月于衢州市人民医院感染科治疗的慢性乙型肝炎患者125例,随机分为观察组62例和对照组63例.观察组给予聚乙二醇干扰素联合胸腺肽肠溶片治疗,对照组给予胸腺肽肠溶片治疗,流式细胞仪法检测患者患者T细胞CXCR3、CCR6表达,采用酶联免疫吸附法检测患者血液中IL-2及可溶性白细胞介素-2受体(sIL-2R)的水平,并对比2组患者治疗效果.结果 治疗后,观察组IL-2、sIL-2R分别为(16.4±5.6)、(9.4±2.1),明显低于对照组,而CXCR3为(5.81±0.9)、CCR6为(5.54±1.2),明显高于对照组,差异有统计学意义(P<0.05);观察组HBsAg、HBeAg、HBV-DNA分别为(1.5±0.4)、(1.6±0.9)、(1.6±0.3),明显低于对照组,差异有统计学意义(P<0.05),观察组ALT、AST、TBIL、IBIL分别为(34.5±8.7)、(31.4±6.9)、(14.6±6.9)、(9.4±2.9),明显低于对照组,差异有统计学意义(P<0.05).结论 干扰素联合胸腺肽肠溶片治疗慢性乙型肝炎有助于提高患者趋化因子受体水平、抑制炎症反应程度,有助于改善乙型肝炎患者肝功能、抑制病毒复制,比单用胸腺肽肠溶片治疗慢性肝炎的效果更好.
展开▼
